{"transactions":[{"id":689008,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T22:10:26.000Z","date":"2026-08-10","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service as a director on each such vesting date."}],"balance_after":175000,"derivative":{"exercise_price":5.39,"expiration_date":"2036-08-10","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001614869-26-000004","document":"form4-08122026_100821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528115/000161486926000004/form4-08122026_100821.xml","form_type":"4"}},{"id":1482004,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-13T00:00:06.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."}],"balance_after":3150,"derivative":{"exercise_price":6.18,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":3150},"source":{"system":"sec-edgar","filing":"0001415889-24-016569","document":"form4-06122024_080602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016569/form4-06122024_080602.xml","form_type":"4"}},{"id":1482003,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T00:00:06.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,615 unvested RSUs."}],"balance_after":13091,"source":{"system":"sec-edgar","filing":"0001415889-24-016569","document":"form4-06122024_080602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924016569/form4-06122024_080602.xml","form_type":"4"}},{"id":1830230,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T14:02:00.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23186,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.94,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":23186},"source":{"system":"sec-edgar","filing":"0001104659-23-080692","document":"tm2321002-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080692/tm2321002-12_4seq1.xml","form_type":"4"}},{"id":1830229,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T14:02:00.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.82,"expiration_date":"2031-05-18","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001104659-23-080692","document":"tm2321002-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080692/tm2321002-12_4seq1.xml","form_type":"4"}},{"id":1830228,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T14:02:00.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":4.48,"expiration_date":"2030-07-14","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001104659-23-080692","document":"tm2321002-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080692/tm2321002-12_4seq1.xml","form_type":"4"}},{"id":1830227,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-13T14:02:00.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each IVERIC restricted stock unit (\"RSU\") represented the contingent right to receive one share of Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-23-080692","document":"tm2321002-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080692/tm2321002-12_4seq1.xml","form_type":"4"}},{"id":1830226,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-13T14:02:00.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each IVERIC restricted stock unit (\"RSU\") represented the contingent right to receive one share of Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-23-080692","document":"tm2321002-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080692/tm2321002-12_4seq1.xml","form_type":"4"}},{"id":1830225,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-13T14:02:00.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32088,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 11, 2023, pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated April 28, 2023, by and among IVERIC bio, Inc. (\"IVERIC\"), Astellas US Holding, Inc., Berry Merger Sub, Inc. (\"Merger Sub\") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. (\"Astellas\"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of IVERIC common stock (\"Common Stock\") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-080692","document":"tm2321002-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080692/tm2321002-12_4seq1.xml","form_type":"4"}},{"id":1845137,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:10.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023."}],"balance_after":2500,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-23-010282","document":"form4-06232023_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010282/form4-06232023_080604.xml","form_type":"4"}},{"id":1845136,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:10.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":5046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":5046,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5046},"source":{"system":"sec-edgar","filing":"0001415889-23-010282","document":"form4-06232023_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010282/form4-06232023_080604.xml","form_type":"4"}},{"id":1845135,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-24T00:00:10.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 6,524 unvested RSUs."}],"balance_after":11691,"source":{"system":"sec-edgar","filing":"0001415889-23-010282","document":"form4-06232023_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010282/form4-06232023_080604.xml","form_type":"4"}},{"id":1845134,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-24T00:00:10.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":3784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,424 unvested RSUs."}],"balance_after":10591,"source":{"system":"sec-edgar","filing":"0001415889-23-010282","document":"form4-06232023_080604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010282/form4-06232023_080604.xml","form_type":"4"}},{"id":1869676,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:37.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":800,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 419 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,221 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The cancelled option was granted on June 16, 2022 and provided for vesting as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869675,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:37.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":840,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 419 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,221 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The cancelled option was granted on November 15, 2021 and provided for vesting with respect to 1/3rd of the shares underlying the option on November 15, 2022 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until November 15, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":105,"expiration_date":"2031-11-14","underlying":"Common Stock","underlying_shares":840},"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869674,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T00:00:37.000Z","date":"2023-03-10","kind":"grant","planned":false,"acquired":true,"shares":497,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"On March 10, 2023, the Issuer issued 497 shares of its common stock to Garland Investments, L.P. (\"Garland\") as a result of the Dosing Milestone."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On March 10, 2023, the Issuer issued 497 shares of its common stock to Garland Investments, L.P. (\"Garland\") as a result of the Dosing Milestone."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held directly by Garland. The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1276,"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869673,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T00:00:37.000Z","date":"2023-02-15","kind":"other","planned":false,"acquired":false,"shares":2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are held directly by Garland. The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":779,"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869672,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T00:00:37.000Z","date":"2023-03-10","kind":"grant","planned":false,"acquired":true,"shares":65634,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"On March 10, 2023, the Issuer issued 65,634 shares of its common stock to Lagunita Biosciences, LLC (\"Lagunita\") as a result of the Dosing Milestone."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On March 10, 2023, the Issuer issued 65,634 shares of its common stock to Lagunita Biosciences, LLC (\"Lagunita\") as a result of the Dosing Milestone."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held directly by Lagunita. The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":168454,"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869671,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T00:00:37.000Z","date":"2023-02-15","kind":"other","planned":false,"acquired":false,"shares":68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held directly by Lagunita. The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":102820,"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869670,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T00:00:37.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":1640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 419 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,221 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,640 unvested RSUs."}],"balance_after":6807,"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869669,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T00:00:37.000Z","date":"2023-03-10","kind":"grant","planned":false,"acquired":true,"shares":2013,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the Issuer issued 2,013 shares of its common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023 (the \"Dosing Milestone\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the Issuer issued 2,013 shares of its common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023 (the \"Dosing Milestone\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":5167,"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1869668,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-03T00:00:37.000Z","date":"2023-02-15","kind":"other","planned":false,"acquired":false,"shares":3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported late due to an inadvertent administrative error."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":3154,"source":{"system":"sec-edgar","filing":"0001415889-23-009139","document":"form4-06022023_080630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009139/form4-06022023_080630.xml","form_type":"4"}},{"id":1884392,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-19T17:47:59.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001410939-23-000080","document":"wk-form4_1684532862.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000080/wk-form4_1684532862.xml","form_type":"4"}},{"id":1893373,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-15T16:52:04.000Z","date":"2023-05-11","kind":"exercise","planned":false,"acquired":false,"shares":14588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14588},"source":{"system":"sec-edgar","filing":"0001410939-23-000078","document":"wk-form4_1684183910.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000078/wk-form4_1684183910.xml","form_type":"4"}},{"id":1893372,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-15T16:52:04.000Z","date":"2023-05-11","kind":"exercise","planned":false,"acquired":true,"shares":14588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."}],"balance_after":32088,"source":{"system":"sec-edgar","filing":"0001410939-23-000078","document":"wk-form4_1684183910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000078/wk-form4_1684183910.xml","form_type":"4"}},{"id":1992837,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-24T17:29:07.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":20728,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's common stock. RSUs convert into the\nissuer's common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20728},"source":{"system":"sec-edgar","filing":"0001562180-23-001846","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218023001846/primarydocument.xml","form_type":"4"}},{"id":1992836,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-24T17:29:07.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":5294,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each Option, whether vested or unvested, that has an exercise price per\nShare that is greater than the Merger Consideration was canceled without the payment of consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option are fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":29,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":5294},"source":{"system":"sec-edgar","filing":"0001562180-23-001846","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218023001846/primarydocument.xml","form_type":"4"}},{"id":1992835,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-24T17:29:07.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":10381,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding option (\"Option\") to purchase Shares granted under any of the Issuer's 2007 Equity Incentive Plan, 2017 Equity Incentive Plan, 2020 Equity Incentive Plan and the Iora Third Amended and Restated 2011 Equity Incentive Plan (collective, the \"Issuer Stock Plans\") or portion thereof that was vested or became vested as of the Effective Time, and had an exercise price per Share that is less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such Option and (ii) the aggregate number of Shares issuable upon exercise of such Option or portion thereof, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years, subject to reporting person's continuous service as of each such date. At the Effective Time, any unvested shares subject to the option was accelerated in full."}],"balance_after":0,"derivative":{"exercise_price":11.56,"expiration_date":"2029-11-20","underlying":"Common Stock","underlying_shares":10381},"source":{"system":"sec-edgar","filing":"0001562180-23-001846","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218023001846/primarydocument.xml","form_type":"4"}},{"id":1992834,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-24T17:29:07.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":4534,"price":18,"value":81612.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the\n\"Merger Agreement\"), dated as of July 20, 2022, by and among Issuer, Amazon.com, Inc. (\"Parent\") and Negroni Merger Sub, Inc., a wholly\nowned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on\nFebruary 22, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each share of Issuer\ncommon stock, par value $0.001 per share (\"Shares\") issued and outstanding immediately prior to the Effective Time was converted\nautomatically into the right to receive $18.00 in cash, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-23-001846","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218023001846/primarydocument.xml","form_type":"4"}},{"id":2205204,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-07-19T16:09:29.000Z","date":"2022-07-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 15, 2020, the Reporting Person was granted 15,000 restricted stock units, which vest annually with respect to 1/3rd of the shares underlying such award until the third anniversary of the grant date, subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 15, 2020, the Reporting Person was granted 15,000 restricted stock units, which vest annually with respect to 1/3rd of the shares underlying such award until the third anniversary of the grant date, subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001410939-22-000084","document":"wf-form4_165826134470561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000084/wf-form4_165826134470561.xml","form_type":"4"}},{"id":2205203,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-19T16:09:29.000Z","date":"2022-07-15","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001410939-22-000084","document":"wf-form4_165826134470561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000084/wf-form4_165826134470561.xml","form_type":"4"}},{"id":2227714,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:45:46.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022."}],"balance_after":40000,"derivative":{"exercise_price":0.36,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-22-006753","document":"form4-06172022_040626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588922006753/form4-06172022_040626.xml","form_type":"4"}},{"id":2242160,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T20:40:20.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":20728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Restricted stock units convert into the issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant."}],"balance_after":20728,"derivative":{"underlying":"Common Stock","underlying_shares":20728},"source":{"system":"sec-edgar","filing":"0001562180-22-004856","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218022004856/primarydocument.xml","form_type":"4"}},{"id":2242159,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T20:40:20.000Z","date":"2022-06-02","kind":"exercise","acquired":false,"shares":4534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Restricted stock units convert into the issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4534},"source":{"system":"sec-edgar","filing":"0001562180-22-004856","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218022004856/primarydocument.xml","form_type":"4"}},{"id":2242158,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T20:40:20.000Z","date":"2022-06-02","kind":"exercise","acquired":true,"shares":4534,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Restricted stock units convert into the issuer's common stock on a one-for-one basis."}],"balance_after":4534,"source":{"system":"sec-edgar","filing":"0001562180-22-004856","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218022004856/primarydocument.xml","form_type":"4"}},{"id":2271833,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-13T18:02:45.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":23186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted a stock option to purchase 23,186 shares of the Registrant's common stock. Subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":23186,"derivative":{"exercise_price":9.94,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":23186},"source":{"system":"sec-edgar","filing":"0001410939-22-000067","document":"wf-form4_165247930506311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000067/wf-form4_165247930506311.xml","form_type":"4"}},{"id":2271832,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-13T18:02:45.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":14588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":14588,"derivative":{"underlying":"Common Stock","underlying_shares":14588},"source":{"system":"sec-edgar","filing":"0001410939-22-000067","document":"wf-form4_165247930506311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000067/wf-form4_165247930506311.xml","form_type":"4"}},{"id":2271831,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-13T18:02:45.000Z","date":"2022-05-11","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001410939-22-000067","document":"wf-form4_165247930506311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000067/wf-form4_165247930506311.xml","form_type":"4"}},{"id":2271830,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T18:02:45.000Z","date":"2022-05-11","kind":"exercise","acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001410939-22-000067","document":"wf-form4_165247930506311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000067/wf-form4_165247930506311.xml","form_type":"4"}},{"id":2507177,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-18T01:01:22.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on November 15, 2021 and vests with respect to 1/3rd of the shares underlying the option on November 15, 2022 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until November 15, 2024."}],"balance_after":42000,"derivative":{"exercise_price":2.1,"expiration_date":"2031-11-14","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001415889-21-005278","document":"form4-11172021_051141.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921005278/form4-11172021_051141.xml","form_type":"4"}},{"id":2507176,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-18T01:01:22.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":38965,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Acquisition, Garland Investments, L.P. (\"Garland\") acquired the right to receive an aggregate of 38,965 shares of the Issuer's common stock (the \"Garland Shares\") in exchange for 646,830 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share. Of the 38,965 Garland Shares, (i) 34,358 Garland Shares are to be issued by the Issuer to Garland on January 3, 2022 and (ii) 4,607 Garland Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Acquisition, Garland Investments, L.P. (\"Garland\") acquired the right to receive an aggregate of 38,965 shares of the Issuer's common stock (the \"Garland Shares\") in exchange for 646,830 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share. Of the 38,965 Garland Shares, (i) 34,358 Garland Shares are to be issued by the Issuer to Garland on January 3, 2022 and (ii) 4,607 Garland Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities will be held directly by Garland. The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report  shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":38965,"source":{"system":"sec-edgar","filing":"0001415889-21-005278","document":"form4-11172021_051141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921005278/form4-11172021_051141.xml","form_type":"4"}},{"id":2507175,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-18T01:01:22.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":5144390,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the Acquisition, Lagunita Biosciences, LLC (\"Lagunita\") acquired the right to receive an aggregate of 5,144,390 shares of the Issuer's common stock (the \"Lagunita Shares\") in exchange for 85,395,439 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share. Of the 5,144,390  Lagunita Shares, (i) 4,536,045 Lagunita Shares are to be issued by the Issuer to Lagunita on January 3, 2022 and (ii) 608,345 Lagunita Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Acquisition, Lagunita Biosciences, LLC (\"Lagunita\") acquired the right to receive an aggregate of 5,144,390 shares of the Issuer's common stock (the \"Lagunita Shares\") in exchange for 85,395,439 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share. Of the 5,144,390  Lagunita Shares, (i) 4,536,045 Lagunita Shares are to be issued by the Issuer to Lagunita on January 3, 2022 and (ii) 608,345 Lagunita Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities will be held directly by Lagunita. The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report  shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":5144390,"source":{"system":"sec-edgar","filing":"0001415889-21-005278","document":"form4-11172021_051141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921005278/form4-11172021_051141.xml","form_type":"4"}},{"id":2507174,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-18T01:01:22.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":157765,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). On November 15, 2021, in connection with the Acquisition, the reporting person acquired the right to receive an aggregate of 157,765 shares of the Issuer's common stock (the \"Shares\") in exchange for 2,618,875 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share.  Of the 157,765 Shares, (i) 139,109 Shares are to be issued by the Issuer to the reporting person on January 3, 2022 and (ii) 18,656 Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). On November 15, 2021, in connection with the Acquisition, the reporting person acquired the right to receive an aggregate of 157,765 shares of the Issuer's common stock (the \"Shares\") in exchange for 2,618,875 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share.  Of the 157,765 Shares, (i) 139,109 Shares are to be issued by the Issuer to the reporting person on January 3, 2022 and (ii) 18,656 Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."}],"balance_after":157765,"source":{"system":"sec-edgar","filing":"0001415889-21-005278","document":"form4-11172021_051141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921005278/form4-11172021_051141.xml","form_type":"4"}},{"id":2630196,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-07-19T16:13:56.000Z","date":"2021-07-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 15, 2020, the Reporting Person was granted 15,000 restricted stock units, which vest annually with respect to 1/3rd of the shares underlying such award until the third anniversary of the grant date, subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 15, 2020, the Reporting Person was granted 15,000 restricted stock units, which vest annually with respect to 1/3rd of the shares underlying such award until the third anniversary of the grant date, subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-21-093460","document":"tm2122558-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465921093460/tm2122558-1_4seq1.xml","form_type":"4"}},{"id":2630195,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-19T16:13:56.000Z","date":"2021-07-15","kind":"exercise","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001104659-21-093460","document":"tm2122558-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465921093460/tm2122558-1_4seq1.xml","form_type":"4"}},{"id":2679136,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-07T20:27:22.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":4534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant."}],"balance_after":4534,"derivative":{"underlying":"Common Stock","underlying_shares":4534},"source":{"system":"sec-edgar","filing":"0001562180-21-004109","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000156218021004109/primarydocument.xml","form_type":"4"}},{"id":2702918,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-05-20T19:54:58.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-070101","document":"tm2117174-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465921070101/tm2117174-5_4seq1.xml","form_type":"4"}},{"id":2702917,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T19:54:58.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":15500,"derivative":{"exercise_price":6.82,"expiration_date":"2031-05-18","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001104659-21-070101","document":"tm2117174-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465921070101/tm2117174-5_4seq1.xml","form_type":"4"}},{"id":3080311,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-07-17T17:27:29.000Z","date":"2020-07-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of the restricted stock units will vest annually with respect to 1/3rd of the shares underlying such award until the third anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of the restricted stock units will vest annually with respect to 1/3rd of the shares underlying such award until the third anniversary of the grant date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-084577","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465920084577/a4.xml","form_type":"4"}},{"id":3080310,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-17T17:27:29.000Z","date":"2020-07-15","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable monthly with respect to 1/36th of the shares underlying such option until the third anniversary of the grant date."}],"balance_after":31000,"derivative":{"exercise_price":4.48,"expiration_date":"2030-07-14","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001104659-20-084577","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465920084577/a4.xml","form_type":"4"}},{"id":3145264,"issuer":{"id":116460,"kind":"organization","name":"1Life Healthcare Inc","symbol":"ONEM"},"owners":[{"id":24035,"kind":"person","name":"Blumenkranz Mark S.","position":1,"cik":"0001614869","reported_name":"Blumenkranz Mark S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-18T17:44:59.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":5294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of (i) the date of the Issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the Reporting Person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant."}],"balance_after":5294,"derivative":{"exercise_price":29,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":5294},"source":{"system":"sec-edgar","filing":"0001209191-20-030189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404123/000120919120030189/doc4.xml","form_type":"4"}}]}